Table 3.
Outcome of TP53-mutated myeloid malignancy patients treated with a combination of hypomethymating agents. CR: Complete Remission, CRi: Complete Remission with Incomplete count recovery, EFS: Event Free Survival, OS: Overall Survival.
| Regimen | Demographics | CR/CRi | EFS | OS | References |
|---|---|---|---|---|---|
| Azacitidine + venetoclax OR Decitabine + venetoclax |
22–86 y/o | 43–67% | Median EFS: 6–7 months | Median OS: 5–7 months | [42,43,44,45,46] |
| Azacitidine + eprenetapopt | 34–87 y/o | 44% | Not available | Median OS: 11 months | [47,48] |
| Azacitidine + magrolimab | Median age 72 y/o | 45% CR, 14% CRi | Not available | Median OS: 12.9 months | [49] |